Trial Profile
A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Aprepitant; Midazolam
- Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Postoperative nausea and vomiting
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 13 Oct 2009 New trial record